Clinical Trials A continuación, se enumeran los ensayos clínicos actuales.278 estudios en Cancer (solo estudios abiertos). Filtra esta lista de estudios por sede, estado, etc. A Study About How Platelets Adhere to the Blood von Willebrand Factor in Healthy Adults Rochester, Minn. The purpose of this study is to learn about how platelets adhere to the blood von Willebrand factor and how known clinical mutations that result in bleeding affect this process. A Study of the Brain & Body Donation Program Scottsdale/Phoenix, Ariz. The purpose of this study is to study the structure and biochemistry of the brain and/or bodily fluid and tissue after death. Comparison of specimens from normal and diseased individuals provide essential clues that lead to a greater understanding of the diseased state which, in turn, will lead to new ideas for therapy. A Study Of Intratumoral Injection Of Autologous Dendritic Cells After High-Dose Conformal External Beam Radiotherapy In Patients With Unresectable Liver Cancer Rochester, Minn. The primary purpose of the pilot study is to evaluate the safety and tolerability of an autologous dendritic cells (DC) vaccine delivered by intra-tumoral injection in patients with primary liver cancer treated with high-dose conformal external beam radiotherapy (EBRT). The primary purpose of the phase II study is to estimate the progression-free survival rate at 2 years post-registration to see if treatment is efficacious compared to historical data. BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib And Nivolumab) To Treat Patients With Advanced Melanoma Or Squamous Cell Head And Neck Cancer, An ImmunoMATCH Pilot Study Jacksonville, Fla., Rochester, Minn., Scottsdale/Phoenix, Ariz. The purpose of this study is to evaluate the feasibility of molecular characterization based on tumor mutational burden (TMB) for participant stratification, as assessed by the proportion of participants with less than or equal to a 21-day turnaround time for biopsy results in Stage I of the study. Also, to evaluate the feasibility of molecular characterization based on TMB and gene expression profiling (GEP) (for TIS - tumor inflammation signature) for stratification in the overall study (Stage I and Stage II). Additinoally, to evaluate the effectiveness by overall response rate (ORR – defined as confirmed and unconfirmed partial responses plus complete responses) of cabozantinib plus nivolumab in each disease cohort, both across and within tumor biomarker subgroups. (Apex) Bezuclastinib In Patients With Advanced Systemic Mastocytosis Scottsdale/Phoenix, Ariz. This is an open-label, two-part Phase 2 study investigating CGT9486 for the treatment of patients with Advanced Systemic Mastocytosis (AdvSM), including patients with Aggressive SM (ASM), SM with Associated Hematologic Neoplasm (SM-AHN), and Mast Cell Leukemia (MCL). Gemini Study To Evaluate The Integration Of Cancer Genetic Testing Into A Cancer Clinical Practice At Mayo Clinic At Arizona Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The purpose of this study is to determine the prevalence of genetic mutations in cancer patients from various ethnic populations seeking care at Mayo Clinic cancer clinics. A Study Of Tucatinib With Trastuzumab And MFOLFOX6 Versus Standard Of Care Treatment In First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) Scottsdale/Phoenix, Ariz., Jacksonville, Fla., Rochester, Minn. The purpose of this study is to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive colorectal cancer. This study will also test what side effects happen when participants take this combination of drugs. A side effect is anything a drug does to the body besides treating your disease. Participants in this study have colorectal cancer that has spread through the body (metastatic) and/or cannot be removed with surgery (unresectable). A Study Of The Health Issues Of Bleeding Disorders Rochester, Minn. The purpose of this study is to monitor and better understand the health issues of people with bleeding disorders. Ascorbic Acid And Chemotherapy For The Treatment Of Relapsed Or Refractory Lymphoma, CCUS, And Chronic Myelomonocytic Leukemia Mankato, Minn., Rochester, Minn., Eau Claire, Wis., La Crosse, Wis. This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may kill more cancer cells. Numeración de páginas Estudios clínicos AnteriorPágina anterior Ir a página 1818 Ir a página 1919 Ir a página 2020 Ir a página 2121 Ir a página 2222 SiguientePróxima página Profesionales médicos Cancer clinical-trials